Xenetic Biosciences Inc (XBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.89M
Last updated: Nov 17, 2026 at 8:24 AM ET
Xenetic Biosciences Inc (XBIO) Stock Forecast
Analysts expect Xenetic Biosciences (XBIO) to earn -$3.32 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.34.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$3.32
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.34
- EPS consensus, revenue $1.90M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.32 | -$3.32 to -$3.32 | 1 | N/A | N/A | 0 |
| Dec 31, 2027 | -$0.34 | -$0.34 to -$0.34 | 1 | $1.90M | $1.90M to $1.90M | 1 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.46.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.32 | -$3.32 | -$3.32 | -$3.32 | -$4.46 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.34 | -$0.34 | -$0.34 | -$0.34 | -$0.43 | N/A |
Frequently Asked Questions About XBIO
What is the XBIO stock forecast?
Consensus analyst estimates put Xenetic Biosciences's EPS at -$3.32 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from XBIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.32, with estimates from -$3.32 to -$3.32 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.34, with estimates from -$0.34 to -$0.34 from 1 analyst.
What revenue do analysts expect from Xenetic Biosciences next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.90M, with estimates from $1.90M to $1.90M.
How many analysts cover XBIO?
1 analyst estimates EPS for Xenetic Biosciences for the fiscal year ending Dec 31, 2026.
XBIO pages: Overview, Earnings, Forecast, Financials, Competitors